Safety Remains Front Line Concern For Oral MS Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck Serono’s cladribine Tablets and Novartis’ fingolimod could be relegated to second line or later treatments.
You may also be interested in...
Oral MS Therapies Move Closer, But Still Far From Approval And Adoption
The arrival of an oral therapy for multiple sclerosis moved closer on Sept. 30, but it will still be an uphill climb: first to get past regulators, and then to gain acceptance from a skeptical field of prescribers
Oral MS Therapies Move Closer, But Still Far From Approval And Adoption
The arrival of an oral therapy for multiple sclerosis moved closer on Sept. 30, but it will still be an uphill climb: first to get past regulators, and then to gain acceptance from a skeptical field of prescribers
Merck Serono Submits Oral Cladribine But That Doesn't End The Oral MS Race
Merck Serono's NDA filing will not prohibit a possible priority review for Novartis' oral FTY720, which had Phase III data released the same day; both applications face close scrutiny with less than ideal clinical trial packages.